{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:02:54Z","timestamp":1767211374747,"version":"3.41.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,23]]},"DOI":"10.7759\/cureus.88625","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:57:17Z","timestamp":1753318637000},"source":"Crossref","is-referenced-by-count":1,"title":["Four-Year Emicizumab Treatment in an Elderly Patient With Acquired Hemophilia A: A Case Report on Perioperative Management Along With a Literature Review"],"prefix":"10.7759","author":[{"given":"Tomoko","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Chikasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Bingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ei","family":"Kinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins P","year":"2012","unstructured":"Collins P, Baudo F, Knoebl P, et al.. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012, 120:47-55. 10.1182\/blood-2012-02-409185","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03467-w","article-title":"ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database","volume":"117","author":"Ogawa Y","year":"2023","unstructured":"Ogawa Y, Amano K, Matsuo-Tezuka Y, et al.. ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database. Int J Hematol. 2023, 117:44-55. 10.1007\/s12185-022-03467-w","journal-title":"Int J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/a-2197-9738","article-title":"Emicizumab for the treatment of acquired hemophilia A: consensus recommendations from the GTH-AHA Working Group","volume":"44","author":"Pfrepper C","year":"2024","unstructured":"Pfrepper C, Klamroth R, Oldenburg J, et al.. Emicizumab for the treatment of acquired hemophilia A: consensus recommendations from the GTH-AHA Working Group. Hamostaseologie. 2024, 44:466-71. 10.1055\/a-2197-9738","journal-title":"Hamostaseologie"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede A","year":"2023","unstructured":"Tiede A, Hart C, Kn\u00f6bl P, et al.. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study. Lancet Haematol. 2023, 10:913-21. 10.1016\/S2352-3026(23)00280-6","journal-title":"Lancet Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima M","year":"2023","unstructured":"Shima M, Amano K, Ogawa Y, et al.. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. 2023, 21:534-45. 10.1016\/j.jtha.2022.10.004","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/a-2384-3585","article-title":"Final analysis results from the AGEHA study: emicizumab prophylaxis for acquired hemophilia A with or without immunosuppressive therapy","volume":"125","author":"Shima M","year":"2025","unstructured":"Shima M, Suzuki N, Nishikii H, et al.. Final analysis results from the AGEHA study: emicizumab prophylaxis for acquired hemophilia A with or without immunosuppressive therapy. Thromb Haemost. 2025, 125:449-59. 10.1055\/a-2384-3585","journal-title":"Thromb Haemost"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg J","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, et al.. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017, 377:809-18. 10.1056\/NEJMoa1703068","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.322.9082","article-title":"Comparison of laparoscopic appendectomy with open appendectomy in treating children with appendicitis","volume":"32","author":"Yu G","year":"2016","unstructured":"Yu G, Han A, Wang W. Comparison of laparoscopic appendectomy with open appendectomy in treating children with appendicitis. Pak J Med Sci. 2016, 32:299-304. 10.12669\/pjms.322.9082","journal-title":"Pak J Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jim\u00e9nez-Yuste V","year":"2022","unstructured":"Jim\u00e9nez-Yuste V, Peyvandi F, Klamroth R, et al.. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY). Res Pract Thromb Haemost. 2022, 6:e12837. 10.1002\/rth2.12837","journal-title":"Res Pract Thromb Haemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14322","article-title":"Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery","volume":"27","author":"Jim\u00e9nez-Yuste V","year":"2021","unstructured":"Jim\u00e9nez-Yuste V, Rodr\u00edguez-Merch\u00e1n EC, Matsushita T, Holme PA. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia. 2021, 27:519-30. 10.1111\/hae.14322","journal-title":"Haemophilia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo F","year":"2012","unstructured":"Baudo F, Collins P, Huth-K\u00fchne A, et al.. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012, 120:39-46. 10.1182\/blood-2012-02-408930","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa T","year":"2017","unstructured":"Kitazawa T, Esaki K, Tachibana T, et al.. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017, 117:1348-57. 10.1160\/TH17-01-0030","journal-title":"Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor\u00a0IXa\/factor\u00a0X bispecific antibody emicizumab","volume":"16","author":"Nogami K","year":"2018","unstructured":"Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, Shima M. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor\u00a0IXa\/factor\u00a0X bispecific antibody emicizumab. J Thromb Haemost. 2018, 16:1078-88. 10.1111\/jth.14022","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.01.007","article-title":"In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab","volume":"222","author":"Yamaguchi T","year":"2023","unstructured":"Yamaguchi T, Shinozawa K, Nagatoishi S, et al.. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab. Thromb Res. 2023, 222:131-9. 10.1016\/j.thromres.2023.01.007","journal-title":"Thromb Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12201","article-title":"Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention","volume":"3","author":"Dane KE","year":"2019","unstructured":"Dane KE, Lindsley JP, Streiff MB, Moliterno AR, Khalid MK, Shanbhag S. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost. 2019, 3:420-3. 10.1002\/rth2.12201","journal-title":"Res Pract Thromb Haemost"},{"key":"ref16","article-title":"Emicizumab prophylaxis in a patient with acquired hemophilia (Texas protocol): case report","volume":"27","author":"Escobar M","year":"2021","unstructured":"Escobar M. Emicizumab prophylaxis in a patient with acquired hemophilia (Texas protocol): case report. Haemophilia. 2021, 27:18-81.","journal-title":"Haemophilia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl P","year":"2021","unstructured":"Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021, 137:410-9. 10.1182\/blood.2020006315","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2021.01.038","article-title":"Unforeseen encounter of acquired hemophilia A in a preoperative case of periampullary carcinoma: a case report","volume":"79","author":"Jena SS","year":"2021","unstructured":"Jena SS, Meher D, Dhankar N. Unforeseen encounter of acquired hemophilia A in a preoperative case of periampullary carcinoma: a case report. Int J Surg Case Rep. 2021, 79:146-9. 10.1016\/j.ijscr.2021.01.038","journal-title":"Int J Surg Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1680166","article-title":"Successful control of bleeding with emicizumab in acquired haemophilia A: a case report","volume":"39","author":"Flommersfeld S","year":"2019","unstructured":"Flommersfeld S, Slonka J, Bieberle I, et al.. Successful control of bleeding with emicizumab in acquired haemophilia A: a case report. Hamostaseologie. 2019, 39:S1-92. 10.1055\/s-0039-1680166","journal-title":"Hamostaseologie"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/10760296241298661","article-title":"Outcomes of emicizumab in acquired hemophilia patients: a systematic review","volume":"30","author":"Ikbel G","year":"2024","unstructured":"Ikbel G, Hela B, Yassine KM, Hamida K, Kamel BS. Outcomes of emicizumab in acquired hemophilia patients: a systematic review. Clin Appl Thromb Hemost. 2024, 30:10760296241298661. 10.1177\/10760296241298661","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/381610-four-year-emicizumab-treatment-in-an-elderly-patient-with-acquired-hemophilia-a-a-case-report-on-perioperative-management-along-with-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:57:18Z","timestamp":1753318638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/381610-four-year-emicizumab-treatment-in-an-elderly-patient-with-acquired-hemophilia-a-a-case-report-on-perioperative-management-along-with-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.88625","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}